Rocket Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $15.27
- Today's High:
- $15.75
- Open Price:
- $15.63
- 52W Low:
- $11.78
- 52W High:
- $24.53
- Prev. Close:
- $15.53
- Volume:
- 923210
Company Statistics
- Market Cap.:
- $1.29 billion
- Book Value:
- 5.005
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -36.09%
- Return on Equity TTM:
- -62.86%
Company Profile
Rocket Pharmaceuticals Inc had its IPO on 2015-02-18 under the ticker symbol RCKT.
The company operates in the Healthcare sector and Biotechnology industry. Rocket Pharmaceuticals Inc has a staff strength of 240 employees.
Stock update
Shares of Rocket Pharmaceuticals Inc opened at $15.63 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $15.27 - $15.75, and closed at $15.29.
This is a -1.55% slip from the previous day's closing price.
A total volume of 923,210 shares were traded at the close of the day’s session.
In the last one week, shares of Rocket Pharmaceuticals Inc have slipped by -4.44%.
Rocket Pharmaceuticals Inc's Key Ratios
Rocket Pharmaceuticals Inc has a market cap of $1.29 billion, indicating a price to book ratio of 4.0724 and a price to sales ratio of 0.
In the last 12-months Rocket Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-253559008. The EBITDA ratio measures Rocket Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Rocket Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -36.09% with a return of equity of -62.86%.
In Q2, Rocket Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Rocket Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.38 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Rocket Pharmaceuticals Inc’s profitability.
Rocket Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -6.3916. Its price to sales ratio in the trailing 12-months stood at 0.
Rocket Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $461.78 million
- Total Liabilities
- $34.35 million
- Operating Cash Flow
- $31.21 million
- Capital Expenditure
- $4.15 million
- Dividend Payout Ratio
- 0%
Rocket Pharmaceuticals Inc ended 2023 with $461.78 million in total assets and $0 in total liabilities. Its intangible assets were valued at $461.78 million while shareholder equity stood at $402.97 million.
Rocket Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $34.35 million in other current liabilities, 805000.00 in common stock, $-837811000.00 in retained earnings and $39.15 million in goodwill. Its cash balance stood at $45.08 million and cash and short-term investments were $307.04 million. The company’s total short-term debt was $2,993,000 while long-term debt stood at $0.
Rocket Pharmaceuticals Inc’s total current assets stands at $312.07 million while long-term investments were $0.00 and short-term investments were $261.96 million. Its net receivables were $0 compared to accounts payable of $31.35 million and inventory worth $0.
In 2023, Rocket Pharmaceuticals Inc's operating cash flow was $31.21 million while its capital expenditure stood at $4.15 million.
Comparatively, Rocket Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $15.29
- 52-Week High
- $24.53
- 52-Week Low
- $11.78
- Analyst Target Price
- $52.6
Rocket Pharmaceuticals Inc stock is currently trading at $15.29 per share. It touched a 52-week high of $24.53 and a 52-week low of $24.53. Analysts tracking the stock have a 12-month average target price of $52.6.
Its 50-day moving average was $17.27 and 200-day moving average was $19.2 The short ratio stood at 13.37 indicating a short percent outstanding of 0%.
Around 375.6% of the company’s stock are held by insiders while 10017.5% are held by institutions.
Frequently Asked Questions About Rocket Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.